Infliximab biosimilar (Biocad)

英夫利西单抗生物类似药 (Biocad)

Report date: 2023/07/01 20:00:34

Base Information

Drug NameInfliximab biosimilar (Biocad)

Drug Alias Name英夫利西单抗生物仿制药 (Biocad)BCD-055

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar

Mechanisms of ActionTumor necrosis factor α inhibitors

TargetsTumor necrosis factor α

Therapy Area/IndicationsArthritis, RheumatoidSpondylitis, Ankylosing

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryRussian FederationBelarusIndia

CombinationsNo

Global Highest StatusPending (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBIOCAD JSC

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesBIOCAD JSC

Active IndicationsN/A

Inactive IndicationsArthritis, RheumatoidSpondylitis, Ankylosing

ATC CodeL04AB02